Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Provided By GlobeNewswire
Last update: Nov 6, 2024
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody
Read more at globenewswire.com
